{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:24Z","timestamp":1787003124111,"version":"build-2736575974"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-71186-5","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:25:17Z","timestamp":1775467517000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Li-Chuan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-701X","authenticated-orcid":false,"given":"Stephen S. Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret M. K.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenqinyao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwui-Wa","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-yuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koon-Chuen","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie Nok-Man","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Lam","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee-Chean","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz-Ho","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Pui","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2953-7728","authenticated-orcid":false,"given":"Jason W. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suet-Yi","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-8687","authenticated-orcid":false,"given":"Anskar Y. H.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-2194","authenticated-orcid":false,"given":"Cheuk-Him","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"71186_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver, N., Schlenk, R. F., Russell, N. H. & Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 33, 299\u2013312 (2019).","journal-title":"Leukemia"},{"key":"71186_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345\u20131377 (2022).","journal-title":"Blood"},{"key":"71186_CR3","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk, R. F. et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133, 840\u2013851 (2019).","journal-title":"Blood"},{"key":"71186_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl, A. E. et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N. Engl. J. Med 381, 1728\u20131740 (2019).","journal-title":"N. Engl. J. Med"},{"key":"71186_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood.2021014586","volume":"140","author":"ES Wang","year":"2022","unstructured":"Wang, E. S. et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood 140, 1845\u20131857 (2022).","journal-title":"Blood"},{"key":"71186_CR6","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba, H. P. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1571\u20131583 (2023).","journal-title":"Lancet"},{"key":"71186_CR7","first-page":"153","volume":"27","author":"S Ganguly","year":"2021","unstructured":"Ganguly, S. et al. Clinical outcomes in patients with FLT3-ITD-mutated relapsed\/refractory acute myelogenous leukemia undergoing hematopoietic stem cell transplantation after quizartinib or salvage chemotherapy in the quANTUM-R trial. Transpl. Cell Ther. 27, 153\u2013162 (2021).","journal-title":"Transpl. Cell Ther."},{"key":"71186_CR8","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood.2021011583","volume":"139","author":"AE Perl","year":"2022","unstructured":"Perl, A. E. et al. Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139, 3366\u20133375 (2022).","journal-title":"Blood"},{"key":"71186_CR9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2010-01-262808","volume":"117","author":"R Chen","year":"2011","unstructured":"Chen, R. et al. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117, 156\u2013164 (2011).","journal-title":"Blood"},{"key":"71186_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-292","volume":"9","author":"W Chen","year":"2010","unstructured":"Chen, W. et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol. Cancer 9, 292 (2010).","journal-title":"Mol. Cancer"},{"key":"71186_CR11","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/s41375-023-02041-5","volume":"37","author":"I Alshamleh","year":"2023","unstructured":"Alshamleh, I. et al. PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia. Leukemia 37, 2367\u20132382 (2023).","journal-title":"Leukemia"},{"key":"71186_CR12","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-20-0738","volume":"11","author":"S Bjelosevic","year":"2021","unstructured":"Bjelosevic, S. et al. Serine biosynthesis is a metabolic vulnerability in FLT3-ITD-driven acute myeloid leukemia. Cancer Discov. 11, 1582\u20131599 (2021).","journal-title":"Cancer Discov."},{"key":"71186_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1182\/blood-2017-12-820035","volume":"131","author":"P Gallipoli","year":"2018","unstructured":"Gallipoli, P. et al. Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition. Blood 131, 1639\u20131653 (2018).","journal-title":"Blood"},{"key":"71186_CR14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add5163","volume":"9","author":"HAK Lapatto","year":"2023","unstructured":"Lapatto, H. A. K. et al. Nicotinamide riboside improves muscle mitochondrial biogenesis, satellite cell differentiation, and gut microbiota in a twin study. Sci. Adv. 9, eadd5163 (2023).","journal-title":"Sci. Adv."},{"key":"71186_CR15","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1172\/JCI138538","volume":"130","author":"B Zhou","year":"2020","unstructured":"Zhou, B. et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J. Clin. Invest 130, 6054\u20136063 (2020).","journal-title":"J. Clin. Invest"},{"key":"71186_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41420-025-02355-6","volume":"11","author":"C Bouvier","year":"2025","unstructured":"Bouvier, C. et al. Role of TRIM24 in the regulation of proteasome-autophagy crosstalk in bortezomib-resistant mantle cell lymphoma. Cell Death Discov. 11, 108 (2025).","journal-title":"Cell Death Discov."},{"key":"71186_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41586-023-06621-4","volume":"622","author":"S Victorelli","year":"2023","unstructured":"Victorelli, S. et al. Apoptotic stress causes mtDNA release during senescence and drives the SASP. Nature 622, 627\u2013636 (2023).","journal-title":"Nature"},{"key":"71186_CR18","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1038\/s41375-022-01650-w","volume":"36","author":"N Jahn","year":"2022","unstructured":"Jahn, N. et al. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603\/RATIFY trial. Leukemia 36, 2218\u20132227 (2022).","journal-title":"Leukemia"},{"key":"71186_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 e1224 (2019).","journal-title":"Cell"},{"key":"71186_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1038\/onc.2015.174","volume":"35","author":"CT Collins","year":"2016","unstructured":"Collins, C. T. & Hess, J. L. Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets. Oncogene 35, 1090\u20131098 (2016).","journal-title":"Oncogene"},{"key":"71186_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03031-7","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang, Y. et al. Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML. Genome Biol. 24, 199 (2023).","journal-title":"Genome Biol."},{"key":"71186_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/leu.2016.329","volume":"31","author":"C Zhou","year":"2017","unstructured":"Zhou, C. et al. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia. Leukemia 31, 1196\u20131205 (2017).","journal-title":"Leukemia"},{"key":"71186_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24656-x","volume":"12","author":"LY Li","year":"2021","unstructured":"Li, L. Y. et al. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer. Nat. Commun. 12, 4362 (2021).","journal-title":"Nat. Commun."},{"key":"71186_CR24","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/S0960-9822(01)00501-2","volume":"11","author":"DM Walker","year":"2001","unstructured":"Walker, D. M. et al. Characterization of MTMR3 Characterization of MTMR3. an inositol lipid 3-phosphatase with novel substrate specificity. Curr. Biol. 11, 1600\u20131605 (2001).","journal-title":"Curr. Biol."},{"key":"71186_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.plefa.2005.04.009","volume":"73","author":"SM Ulven","year":"2005","unstructured":"Ulven, S. M., Dalen, K. T., Gustafsson, J. A. & Nebb, H. I. LXR is crucial in lipid metabolism. Prostaglandins Leukot. Ess. Fat. Acids 73, 59\u201363 (2005).","journal-title":"Prostaglandins Leukot. Ess. Fat. Acids"},{"key":"71186_CR26","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2024.01.030","volume":"187","author":"B Qiu","year":"2024","unstructured":"Qiu, B. et al. Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell 187, 1177\u20131190 e1118 (2024).","journal-title":"Cell"},{"key":"71186_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132, 598\u2013607 (2018).","journal-title":"Blood"},{"key":"71186_CR28","doi-asserted-by":"publisher","first-page":"359ra129","DOI":"10.1126\/scitranslmed.aaf3735","volume":"8","author":"SS Lam","year":"2016","unstructured":"Lam, S. S. et al. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Sci. Transl. Med. 8, 359ra129 (2016).","journal-title":"Sci. Transl. Med."},{"key":"71186_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0014-5793(93)80290-B","volume":"331","author":"E Nimmesgern","year":"1993","unstructured":"Nimmesgern, E. & Hartl, F. U. ATP-dependent protein refolding activity in reticulocyte lysate. Evidence for the participation of different chaperone components. FEBS Lett. 331, 25\u201330 (1993).","journal-title":"FEBS Lett."},{"key":"71186_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2009.09.023","volume":"36","author":"JI Leu","year":"2009","unstructured":"Leu, J. I., Pimkina, J., Frank, A., Murphy, M. E. & George, D. L. A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell 36, 15\u201327 (2009).","journal-title":"Mol. Cell"},{"key":"71186_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-009-1194-3","volume":"66","author":"AJ Massey","year":"2010","unstructured":"Massey, A. J. et al. A novel, small molecule inhibitor of Hsc70\/Hsp70 potentiates Hsp90 inhibitor-induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother. Pharm. 66, 535\u2013545 (2010).","journal-title":"Cancer Chemother. Pharm."},{"key":"71186_CR32","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41392-021-00672-7","volume":"6","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia. Signal Transduct. Target Ther. 6, 334 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"71186_CR33","doi-asserted-by":"publisher","first-page":"829520","DOI":"10.3389\/fonc.2022.829520","volume":"12","author":"Z Albakova","year":"2022","unstructured":"Albakova, Z., Mangasarova, Y., Albakov, A. & Gorenkova, L. HSP70 and HSP90 in cancer: cytosolic, endoplasmic reticulum and mitochondrial chaperones of tumorigenesis. Front Oncol. 12, 829520 (2022).","journal-title":"Front Oncol."},{"key":"71186_CR34","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.2023019782","volume":"142","author":"CH Man","year":"2023","unstructured":"Man, C. H. et al. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML. Blood 142, 2002\u20132015 (2023).","journal-title":"Blood"},{"key":"71186_CR35","unstructured":"Ng, K. L. Decitabine and immune activation in TP53 mutated MDS\/AML [Conference Abstract]. 6th International Conference:Acute Myeloid Leukemia Molecular and Translational Advances in Biology and Treatment, European School of Haematology, Estoril, Portugal (2023)."},{"key":"71186_CR36","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1182\/blood.2022016528","volume":"141","author":"S Agrawal-Singh","year":"2023","unstructured":"Agrawal-Singh, S. et al. HOXA9 forms a repressive complex with nuclear matrix-associated protein SAFB to maintain acute myeloid leukemia. Blood 141, 1737\u20131754 (2023).","journal-title":"Blood"},{"key":"71186_CR37","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ni1268","volume":"6","author":"AM Intlekofer","year":"2005","unstructured":"Intlekofer, A. M. et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6, 1236\u20131244 (2005).","journal-title":"Nat. Immunol."},{"key":"71186_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"71186_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838484","volume":"13","author":"A Knorck","year":"2022","unstructured":"Knorck, A. et al. Cytotoxic efficiency of human CD8(+) T cell memory subtypes. Front Immunol. 13, 838484 (2022).","journal-title":"Front Immunol."},{"key":"71186_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","volume":"68","author":"SB Hay","year":"2018","unstructured":"Hay, S. B., Ferchen, K., Chetal, K., Grimes, H. L. & Salomonis, N. The Human Cell Atlas bone marrow single-cell interactive web portal. Exp. Hematol. 68, 51\u201361 (2018).","journal-title":"Exp. Hematol."},{"key":"71186_CR41","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nm1483","volume":"12","author":"L Jin","year":"2006","unstructured":"Jin, L., Hope, K. J., Zhai, Q., Smadja-Joffe, F. & Dick, J. E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167\u20131174 (2006).","journal-title":"Nat. Med."},{"key":"71186_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/0008-5472.CAN-18-2932","volume":"80","author":"K Sachs","year":"2020","unstructured":"Sachs, K. et al. Single-cell gene expression analyses reveal distinct self-renewing and proliferating subsets in the leukemia stem cell compartment in acute myeloid leukemia. Cancer Res 80, 458\u2013470 (2020).","journal-title":"Cancer Res"},{"key":"71186_CR43","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","volume":"1","author":"BM Stevens","year":"2020","unstructured":"Stevens, B. M. et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Nat. Cancer 1, 1176\u20131187 (2020).","journal-title":"Nat. Cancer"},{"key":"71186_CR44","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1038\/s12276-024-01260-9","volume":"56","author":"SH Lim","year":"2024","unstructured":"Lim, S. H. et al. PLD1 is a key player in cancer stemness and chemoresistance: Therapeutic targeting of cross-talk between the PI3K\/Akt and Wnt\/beta-catenin pathways. Exp. Mol. Med. 56, 1479\u20131487 (2024).","journal-title":"Exp. Mol. Med."},{"key":"71186_CR45","doi-asserted-by":"publisher","first-page":"100128","DOI":"10.1016\/j.mocell.2024.100128","volume":"47","author":"D Kim","year":"2024","unstructured":"Kim, D., Yoon, M. S., Lee, J., Park, S. Y. & Han, J. S. Effects of phospholipase D1-inhibitory peptide on the growth and metastasis of gastric cancer cells. Mol. Cells 47, 100128 (2024).","journal-title":"Mol. Cells"},{"key":"71186_CR46","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock, L. K. et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood 137, 3093\u20133104 (2021).","journal-title":"Blood"},{"key":"71186_CR47","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1182\/blood-2022-169991","volume":"140","author":"F Haddad","year":"2022","unstructured":"Haddad, F. et al. Evaluation of emergent FLT3 mutations (FLT3m) at relapse in patients (Pts) with wild-type FLT3 Acute Myeloid Leukemia (AML). Blood 140, 3196\u20133198 (2022).","journal-title":"Blood"},{"key":"71186_CR48","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","volume":"117","author":"T Sato","year":"2011","unstructured":"Sato, T. et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117, 3286\u20133293 (2011).","journal-title":"Blood"},{"key":"71186_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/bjh.12599","volume":"164","author":"X Yang","year":"2014","unstructured":"Yang, X., Sexauer, A. & Levis, M. Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase. Br. J. Haematol. 164, 61\u201372 (2014).","journal-title":"Br. J. Haematol."},{"key":"71186_CR50","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2013-07-512194","volume":"123","author":"CH Man","year":"2014","unstructured":"Man, C. H. et al. A novel tescalcin-sodium\/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood 123, 2530\u20132539 (2014).","journal-title":"Blood"},{"key":"71186_CR51","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1182\/bloodadvances.2018022921","volume":"3","author":"YT Chang","year":"2019","unstructured":"Chang, Y. T. et al. Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3\/ITD AML from tyrosine kinase inhibitors. Blood Adv. 3, 908\u2013916 (2019).","journal-title":"Blood Adv."},{"key":"71186_CR52","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/sj.leu.2404776","volume":"21","author":"TM Kohl","year":"2007","unstructured":"Kohl, T. M. et al. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21, 1763\u20131772 (2007).","journal-title":"Leukemia"},{"key":"71186_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08263-x","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat. Commun. 10, 244 (2019).","journal-title":"Nat. Commun."},{"key":"71186_CR54","doi-asserted-by":"publisher","first-page":"e2116427118","DOI":"10.1073\/pnas.2116427118","volume":"118","author":"F Ferraro","year":"2021","unstructured":"Ferraro, F. et al. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proc. Natl. Acad. Sci. USA 118, e2116427118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"71186_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1252-2","volume":"15","author":"M Goswami","year":"2017","unstructured":"Goswami, M. et al. Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy. J. Transl. Med 15, 155 (2017).","journal-title":"J. Transl. Med"},{"key":"71186_CR56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.exphem.2021.11.003","volume":"105","author":"KJG Kenswil","year":"2022","unstructured":"Kenswil, K. J. G. et al. Immune composition and its association with hematologic recovery after chemotherapeutic injury in acute myeloid leukemia. Exp. Hematol. 105, 32\u201338 e32 (2022).","journal-title":"Exp. Hematol."},{"key":"71186_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14049","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng, G. X. Y. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"71186_CR58","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"71186_CR59","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/s41586-024-07251-0","volume":"628","author":"Y Gu","year":"2024","unstructured":"Gu, Y. et al. Immune microniches shape intestinal T(reg) function. Nature 628, 854\u2013862 (2024).","journal-title":"Nature"},{"key":"71186_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02584-9","volume":"23","author":"S Choudhary","year":"2022","unstructured":"Choudhary, S. & Satija, R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 23, 27 (2022).","journal-title":"Genome Biol."},{"key":"71186_CR61","doi-asserted-by":"publisher","first-page":"P10008","DOI":"10.1088\/1742-5468\/2008\/10\/P10008","volume":"2008","author":"VD Blondel","year":"2008","unstructured":"Blondel, V. D., Guillaume, J.-L., Lambiotte, R. & Lefebvre, E. Fast unfolding of communities in large networks. J. Stat. Mech.: Theory Exp. 2008, P10008 (2008).","journal-title":"J. Stat. Mech.: Theory Exp."},{"key":"71186_CR62","doi-asserted-by":"publisher","first-page":"giy083","DOI":"10.1093\/gigascience\/giy083","volume":"7","author":"L Zappia","year":"2018","unstructured":"Zappia, L. & Oshlack, A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. GigaScience 7, giy083 (2018).","journal-title":"GigaScience"},{"key":"71186_CR63","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.cell.2021.03.056","volume":"184","author":"M Ota","year":"2021","unstructured":"Ota, M. et al. Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases. Cell 184, 3006\u20133021.e3017 (2021).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71186-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71186-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:02:35Z","timestamp":1780448555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-71186-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["71186"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-71186-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4902"}}